Members with long QT syndrome may like to consider registering with CredibleMeds to be kept up to date with any changes to the QT drugs to avoid list https://crediblemeds.org/everyone/.
We have recently received the following message through CredibleMeds:
On January 14th, AZCERT added the anticancer drug Glasdegib (Daurismo) to the Possible Risk of torsades de pointes (TdP) list because we have found evidence of QT prolongation but, at this time, no convincing evidence of TdP.
On February 17th, the following drugs were added to the lists:
Lofexidine (Lucemyra, a drug for treatment of opiate withdrawal) was added to the Possible Risk of TdP list because we have found evidence of QT prolongation but no convincing evidence, at this time, of TdP.
Hydroquinidine (an antiarrhythmic drug) has been added to the Known Risk of TdP list because we have found evidence of TdP cases reported with its use.
Xylometazoline (a decongestant nasal spray with many brand names) has been added to the list of drugs that patients with congenital long QT syndrome should avoid if possible.